Although there is evidence that the atypical antipsychotic, clozapine, may lead to cost savings in patients with refractory schizophrenia the cost-effectiveness of the other atypical antipsychotics remains in question.
Although there is evidence that the atypical antipsychotic, clozapine, may lead to cost savings in patients with refractory schizophrenia the cost-effectiveness of the other atypical antipsychotics remains in question.
尽管有证据表明，非典型抗精神病药物氯氮平，可使难治性精神分裂症患者节省费用，而其它非典型抗精神病药物的费用-效能仍存疑问。